alexa A New Human Uterine Cervical Mesenchymal Stem Cell Line With Potent Breast Tumor Growth-inhibiting Properties
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Cell Science & Stem Cell Research
June 24-26, 2014 Valencia Conference Centre, Valencia, Spain

Noem? Eir?, Juan Sendon-Lago, Samuel Seoane, Maria Luz Lamelas, Tom?s Garcia-Caballero, Jos? Schneider, Roman Perez-Fernandez and Francisco J Vizoso
Posters: J Cell Sci Ther
DOI: 10.4172/2157-7013.S1.029
Abstract
T he role of mesenchymal stem cells (MSCs) in tumorigenesis has been widely studied. However, contradictory results have been described regarding induced pro- or anti-tumor effects. The present study uses a newly discovered source of MSCs to study breast cancer. MSCs have been isolated from normal human uterine cervix (human uterine cervical stem cells, hUCESCs) by means of routine Pap cervical smears. This method of obtaining hUCESCs provides several advantages. It is much less invasive and painful that those used to obtain other MSCs (i.e. from bone marrow or adipose tissue). In addition, cells can be obtained throughout life, unlike placenta or umbilical cord MSCs, and be isolated in high quantities with a high proliferation rate. After administering hUCESC-conditioned medium (CM) to a highly invasive breast cancer MDA-MB-231 cell line, is obtained a reduced cell proliferation, a modified cell cycle, induced apoptosis, and decreased invasion. Moreover, in a xenograft mouse tumor model, intratumoral administration of hUCESC-CM reduced tumor growth and increased overall survival. These data suggest that hUCESCs could be used in research as to experimental or clinical applications in cancer therapy
Biography
Noem? Eir? has studied her Bachelor?s degree in Biochemistry and Genomic in France and has completed her PhD at the age of 28 years from Oviedo University (Spain). She has worked in the Functional Genomic Unit of the Institut Gustave Roussy (France) and in the Department of Immunology and Oncology of Centro Nacional de Biotecnolog?a (Spain). Currently, she is a Researcher of the Research Unit of the Fundaci?n Hospital de Jove. She is a co-author of 2 patents and has published 19 papers in reputed journals.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords